Skip to main content
. 2012 Sep 27;7(9):e44979. doi: 10.1371/journal.pone.0044979

Figure 5. Decreased Lxn expression in stem/progenitor-enriched CD34+ cells in patients with leukemia and lymphoma.

Figure 5

(A) Lxn mRNA expression in bone marrow and peripheral blood CD34+ cells from leukemia and lymphoma patients and normal individuals. Lxn mRNA level was measured by quantitative real-time PCR and shown as mean (±1 SD) (n = 12). Normal samples were derived from cord blood (CB), bone marrow (BM) of young at 31 (Y1) and 39 (Y2) years old and old at 85 (O1) and 97 (O2) years old people. The patient samples include acute myeloid leukemia (AML), T cell pro-lympho leukemia (Pctl), plasma cell leukemia (PCL), acute T cell lymphoma (ATLL) and acute lymphoid leukemia (ALL, preB phenotype). (B) LXN protein expression in bone marrow and peripheral blood CD34+ cells from leukemia and lymphoma patients and normal individuals. Western blot was performed on the corresponding samples shown in panel (A) plus five more samples, including two young (Y3 and Y4; at 40 and 31 years old respectively), two old (O3 and O4; at 80 and 87 years old respectively) and chronic myeloid leukemia (CML). The blots (bottom) and their quantification (top) profiles demonstrate the significantly decreased Lxn protein level in leukemic CD34+ and lymphoma cells (P = 0.03).